F/m Emerald Life Sciences Innovation ETF

7.2% under the 52-week high of 48.78 on 19 Aug 2026. 52-week low 32.84 on 30 Mar 2026. Last 15 sessions, 12.7% high to low

the line is the 50-bar volume average

Setup. RS line 81
CANSLIM 1 of 6 — fails: Performance: Year +50% — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 5 of 6 — not on the tape: Relative Volume: Under 1
Minervini 3 of 4 — fails: Performance: Year +50%
Zanger 3 of 5 — fails: Performance: Week +10% — not on the tape: Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Performance: Year +50% — not on the tape: Average Volume: Over 500K
Breakout 2 of 4 — fails: 52-Week High/Low: New High — not on the tape: Relative Volume: Over 2
Growth 0 of 4 — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 0 of 5 — not on the tape: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25; Current Ratio: Over 1
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Performance: Year +50% — not on the tape: Float: Under 100M; Average Volume: Over 500K
Accumulation 2 of 4 — not on the tape: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%
Relative Strength 1 of 3 — fails: Performance: Year +100% — not on the tape: Average Volume: Over 500K